Solventum Corporation $SOLV Position Lessened by QV Investors Inc.

QV Investors Inc. cut its position in shares of Solventum Corporation (NYSE:SOLV) by 29.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 154,502 shares of the company’s stock after selling 64,190 shares during the period. QV Investors Inc. owned 0.09% of Solventum worth $13,619,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SOLV. WINTON GROUP Ltd purchased a new position in Solventum during the second quarter worth approximately $3,402,000. Diamond Hill Capital Management LLC Investment Advisor acquired a new stake in Solventum in the second quarter valued at approximately $150,066,000. Squarepoint Ops LLC grew its holdings in Solventum by 6,103.8% in the second quarter. Squarepoint Ops LLC now owns 243,128 shares of the company’s stock valued at $18,757,000 after purchasing an additional 239,209 shares during the period. Lone Peak Global Investors LLC increased its position in shares of Solventum by 38.5% in the second quarter. Lone Peak Global Investors LLC now owns 433,128 shares of the company’s stock valued at $33,416,000 after buying an additional 120,352 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Solventum in the second quarter valued at approximately $1,018,000.

Solventum Trading Up 1.5%

Shares of Solventum stock opened at $86.35 on Wednesday. The firm has a market capitalization of $14.70 billion, a PE ratio of 10.56, a P/E/G ratio of 1.31 and a beta of 0.63. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $94.16. The firm’s 50-day moving average price is $88.68 and its 200 day moving average price is $80.31. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%. The company had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.15 billion. During the same period in the previous year, the business earned $1.69 EPS. Solventum’s quarterly revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, sell-side analysts predict that Solventum Corporation will post 7.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. KeyCorp increased their target price on Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. BMO Capital Markets started coverage on shares of Solventum in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price target on the stock. Weiss Ratings raised shares of Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. Stifel Nicolaus boosted their price target on shares of Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, UBS Group upped their price objective on shares of Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Ten analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $92.80.

Solventum Profile

Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.